MCID: OPT008
MIFTS: 37

Optic Nerve Neoplasm

Categories: Cancer diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Optic Nerve Neoplasm

MalaCards integrated aliases for Optic Nerve Neoplasm:

Name: Optic Nerve Neoplasm 12 14
Optic Nerve Neoplasms 42 69
Tumor of Second Cranial Nerve 12
Neoplasm of Optic Nerve 12
Tumour of Optic Nerve 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3419
MeSH 42 D019574
NCIt 47 C4801
ICD10 33 C72.3
UMLS 69 C0524802

Summaries for Optic Nerve Neoplasm

MalaCards based summary : Optic Nerve Neoplasm, also known as optic nerve neoplasms, is related to neurofibromatosis-noonan syndrome and breast apocrine carcinoma in situ. An important gene associated with Optic Nerve Neoplasm is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Neuroscience and Glioblastoma Multiforme. The drugs Ephedrine and Pseudoephedrine have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and eye, and related phenotypes are Increased proliferation and behavior/neurological

Related Diseases for Optic Nerve Neoplasm

Diseases related to Optic Nerve Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
id Related Disease Score Top Affiliating Genes
1 neurofibromatosis-noonan syndrome 10.9 NF1 NF2
2 breast apocrine carcinoma in situ 10.8 NF1 SYP
3 chilaiditi syndrome 10.7 MAP2 SYP
4 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.6 CDKN2A NF2
5 pediatric fibrosarcoma 10.5 NF1 NF2
6 adenofibroma 10.5 MAP2 NES SYP
7 brain stem ependymoma 10.5 NES NF2 SYP
8 verruciform xanthoma of skin 10.5 ENO2 NF2
9 paranasal sinus cancer 10.5 ENO2 SYP
10 epidermolysa bullosa simplex with muscular dystrophy 10.5 NES NF2 SYP
11 ampulla of vater small cell carcinoma 10.5 ENO2 SYP
12 situs inversus totalis with cystic dysplasia of kidneys and pancreas 10.5 ENO2 SYP
13 gallbladder papillary carcinoma 10.5 ENO2 NF2
14 brain stem astrocytic neoplasm 10.5 NF1 TP53
15 cervical keratinizing squamous cell carcinoma 10.5 ENO2 NF1
16 childhood choriocarcinoma of the ovary 10.5 ENO2 SYP
17 cervical adenitis 10.5 CDKN2A KRT5
18 enteric pattern testicular yolk sac tumor 10.5 ENO2 NF1
19 glomus tumor 10.5 ENO2 SYP
20 cystitis cystica 10.5 ENO2 SYP
21 small intestine cancer, childhood 10.5 ENO2 SYP
22 benign pleural mesothelioma 10.5 CDKN2A NF1 NF2
23 pemphigus foliaceus 10.4 ENO2 SYP
24 chondroid chordoma 10.4 ENO2 SYP
25 renal pelvis urothelial papilloma 10.4 NF2 TP53
26 demyelinating disease 10.4 ENO2 NF1 NF2
27 mast cell neoplasm 10.4 ENO2 SYP
28 cauda equina intradural extramedullary astrocytoma 10.4 ENO2 SYP
29 hole retinal cyst 10.4 ENO2 LOX
30 2q31.1 microdeletion syndrome 10.3 ENO2 MAP2 SYP
31 intraductal breast myoepitheliosis 10.3 NF2 TP53
32 cauda equina neoplasm 10.3 ENO2 NF2 SYP
33 diencephalic astrocytomas 10.3 CDKN2A NF1 SYP
34 anaplastic oligodendroglioma 10.3 NF2 SYP
35 pleomorphic xanthoastrocytoma 10.3 ENO2 SYP
36 opitz-gbbb syndrome 10.3 ENO2 NF1 SYP
37 lipid-cell variant infiltrating bladder urothelial carcinoma 10.3 KRT5 TP53
38 axonal neuropathy 10.3 ENO2 NES SYP
39 arteriolosclerosis 10.3 CDKN2A KRT5 NF2
40 marinesco-sjogren-like syndrome 10.3 ACE TP53
41 sudden sensorineural hearing loss 10.3 ENO2 NES SYP
42 pediatric ependymoma 10.3 ENO2 NES SYP
43 mixed epithelial stromal tumour 10.3 ENO2 NES SYP
44 brainstem intraparenchymal clear cell meningioma 10.3 NES TP53
45 cervical adenoid cystic carcinoma 10.2 CDKN2A TP53
46 small intestine leiomyoma 10.2 KRT5 TP53
47 pleural empyema 10.2 NF2 SYP TP53
48 third cranial nerve disease 10.2 NF2 TP53
49 lymphoplasmacytic lymphoma 10.2 NF1 NF2 TP53
50 osteoblastoma 10.2 ENO2 KRT5 SYP

Graphical network of the top 20 diseases related to Optic Nerve Neoplasm:



Diseases related to Optic Nerve Neoplasm

Symptoms & Phenotypes for Optic Nerve Neoplasm

GenomeRNAi Phenotypes related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

MGI Mouse Phenotypes related to Optic Nerve Neoplasm:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 ACE CDKN2A ENO2 FABP7 KRT5 LOX
2 growth/size/body region MP:0005378 10 ACE CDKN2A ENO2 H2AFX KRT5 MAP2
3 endocrine/exocrine gland MP:0005379 9.92 MIB1 NF1 NF2 TP53 ACE CDKN2A
4 homeostasis/metabolism MP:0005376 9.9 NF2 OPTN TP53 ACE CDKN2A FABP7
5 mortality/aging MP:0010768 9.73 NF2 OPTN TP53 ACE CDKN2A H2AFX
6 neoplasm MP:0002006 9.1 ACE CDKN2A H2AFX NF1 NF2 TP53

Drugs & Therapeutics for Optic Nerve Neoplasm

Drugs for Optic Nerve Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ephedrine Approved Phase 4 299-42-3 9294
2
Pseudoephedrine Approved Phase 4 90-82-4 7028
3 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
4 Adrenergic Agents Phase 4
5 Adrenergic Agonists Phase 4
6 Adrenergic alpha-2 Receptor Agonists Phase 4
7 Adrenergic alpha-Agonists Phase 4
8 Antihypertensive Agents Phase 4
9 Autonomic Agents Phase 4,Phase 1
10 Brimonidine Tartrate Phase 4 70359-46-5
11 Carboxymethylcellulose Sodium Phase 4
12 Cathartics Phase 4
13 Gastrointestinal Agents Phase 4,Phase 1
14 Laxatives Phase 4
15 Nasal Decongestants Phase 4
16 Neurotransmitter Agents Phase 4
17 Ophthalmic Solutions Phase 4
18 Pharmaceutical Solutions Phase 4,Phase 2
19 Respiratory System Agents Phase 4
20 Tetrahydrozoline Phase 4
21 Vasoconstrictor Agents Phase 4
22
Topotecan Approved, Investigational Phase 3,Phase 2 119413-54-6, 123948-87-8 60700
23
Dacarbazine Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 4342-03-4 5351166
24
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 85622-93-1 5394
25
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
26
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
27
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
28
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
29
Mesna Approved Phase 3,Phase 2 3375-50-6 598
30
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
31
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
32 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
34 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1
35 Anesthetics Phase 3
36 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
37 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
39 Antirheumatic Agents Phase 3,Phase 2,Phase 1
40 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
41 Antimitotic Agents Phase 3,Phase 1,Phase 2
42 Etoposide phosphate Phase 3,Phase 2,Phase 1
43
Irinotecan Approved, Investigational Phase 2,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
44
Bevacizumab Approved, Investigational Phase 1, Phase 2, Early Phase 1 216974-75-3
45
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
46
Lenograstim Approved Phase 2,Phase 1 135968-09-1
47
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
48
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
49
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
50
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837

Interventional clinical trials:

(show top 50) (show all 81)

id Name Status NCT ID Phase Drugs
1 Preoperative Brimonidine on IOP of Patients Undergoing RALP Recruiting NCT02818816 Phase 4 brimonidine tartrate 0.2%
2 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer Completed NCT00390806 Phase 3 HYCAMTIN, oral capsules
3 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting NCT00186888 Phase 3 Vincristine, Carboplatin;Vincristine + Topotecan;Vincristine + Carboplatin + Etoposide;Vincristine + Cyclophosphamide + Doxorubicin;Vincristine+Carboplatin+Etoposide
4 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
5 Whole-Brain Radiotherapy (WBRT) Versus WBRT and Integrated Boost Using Helical Tomotherapy for Multiple Brain Metastases Unknown status NCT00876759 Phase 2
6 Randomized Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial. Unknown status NCT01795300 Phase 1, Phase 2
7 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
8 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
9 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
10 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
11 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
12 Multisession Radiosurgery for Optic Nerve Sheath Meningiomas Recruiting NCT02594709 Phase 2
13 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Recruiting NCT02839720 Phase 2 Selumetinib
14 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
15 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
16 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
17 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
18 Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma Recruiting NCT01783535 Phase 2 vincristine;topotecan;filgrastim;PEG-filgrastim;carboplatin;etoposide;cyclophosphamide;MESNA;doxorubicin
19 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
20 Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer Enrolling by invitation NCT02054052 Phase 2 Bevacizumab
21 Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy Not yet recruiting NCT03285932 Phase 2
22 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2 Aspirin;Placebo
23 Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas Terminated NCT01338857 Phase 2 Sorafenib (Nexavar)
24 EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Completed NCT00056199 Phase 1 EYE001
25 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
26 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
27 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
28 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
29 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
30 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
31 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
32 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
33 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
34 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00929903 Phase 1 pazopanib hydrochloride
35 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
36 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Completed NCT00012181 Phase 1 alvocidib
37 Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Completed NCT00089765 Phase 1 Ranibizumab
38 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
39 Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors Recruiting NCT02372409 Phase 1 Doxorubicin;Etoposide
40 Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting NCT02780804 Phase 1 Entinostat
41 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Recruiting NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
42 Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Active, not recruiting NCT02415153 Phase 1 Pomalidomide
43 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
44 Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON) Terminated NCT00278486 Phase 1
45 A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors Unknown status NCT02225197
46 Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. Unknown status NCT02078401
47 The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor Unknown status NCT01377701
48 Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab Unknown status NCT01331616 Early Phase 1 Bevacizumab (Avastin)
49 The Effect of Colonoscopy on Intralocular Pressure Unknown status NCT02321722
50 Perioperative Evaluation of Intracranial Hypertension by Ultrasound Measurement of Variations in the Diameter of the Sheath of the Optic Nerve in the Excision of a Tumor or Biopsy Supratentorial Brain Completed NCT01864499

Search NIH Clinical Center for Optic Nerve Neoplasm

Cochrane evidence based reviews: optic nerve neoplasms

Genetic Tests for Optic Nerve Neoplasm

Anatomical Context for Optic Nerve Neoplasm

MalaCards organs/tissues related to Optic Nerve Neoplasm:

39
Brain, Lung, Eye, Kidney, T Cells, Spinal Cord, Pituitary

Publications for Optic Nerve Neoplasm

Variations for Optic Nerve Neoplasm

Expression for Optic Nerve Neoplasm

Search GEO for disease gene expression data for Optic Nerve Neoplasm.

Pathways for Optic Nerve Neoplasm

Pathways related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.61 ENO2 FABP7 MAP2 NF1 NF2 SYP
2 11.5 CDKN2A NF1 NF2 TP53
3 11.16 FABP7 MAP2 NES SYP

GO Terms for Optic Nerve Neoplasm

Cellular components related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 8.62 FABP7 NF2

Biological processes related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of protein kinase activity GO:0006469 9.5 CDKN2A NF1 NF2
2 negative regulation of cell proliferation GO:0008285 9.35 CDKN2A FABP7 NF1 NF2 TP53
3 Ras protein signal transduction GO:0007265 9.33 CDKN2A NF1 TP53
4 replicative senescence GO:0090399 9.26 CDKN2A TP53
5 negative regulation of cell-matrix adhesion GO:0001953 8.8 CDKN2A NF1 NF2

Sources for Optic Nerve Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....